產(chǎn)品名稱：HH人皮膚T淋巴瘤細(xì)胞、HH人皮膚T淋巴瘤細(xì)胞、HH人皮膚T淋巴瘤細(xì)胞、HH人皮膚T淋巴瘤細(xì)胞；

discusses the mechanisms by which fibrosis might subvert tumor immunity and how to overcome these mechanisms.Immune checkpoint inhibitors and adoptive transfer of gene-engineered T cells have emerged as novel therapeutic modalities for hard-to-treat solid tumors; however, many patients are refractory to these immunotherapies, and the mechanisms underlying tumor immune resistance have not been fully elucidated. By